SG11201908247RA - T cell receptor like antibodies that bind to p53-mhc class i complex - Google Patents

T cell receptor like antibodies that bind to p53-mhc class i complex

Info

Publication number
SG11201908247RA
SG11201908247RA SG11201908247RA SG11201908247RA SG 11201908247R A SG11201908247R A SG 11201908247RA SG 11201908247R A SG11201908247R A SG 11201908247RA SG 11201908247R A SG11201908247R A SG 11201908247RA
Authority
SG
Singapore
Prior art keywords
singapore
sep
grove
biomedical
com
Prior art date
Application number
Inventor
Cheng-I Wang
Lionel Low
Angeline Goh
Bei Wang
Wen-Hsin Lee
Ching-Wen Huang
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201908247RA publication Critical patent/SG11201908247RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)

Abstract

11 , 10OP9EN90AP6OI : Nn60 9FILPO1APKILKININELE50NP NRFSGSKSOTSASLAITOLCNEDEADNICOODSNISAWVFOGOTICTILSOPKAAPSVIL FPPESEELPANICATIVCUSOFYPGAVIVAMMISSPVIGOVETUPSKCI.NNYANISVI SLIPEOWK6NI(IVSOOVMEGS1 -vEK - FW,ECS DEO 10140:1) LC-COR1: LC COPS: LC-COM: TOSSSNIGAINE11 (SE0 10 NO:I 7, NINRPS (6E0 ID NW.) PSVOSKLSAWY (3E010 NO:1s) PIC1 PICI em• IL, 1E11 OSVITOPPSVSGAPGOR,ISO, _,,MBIUMMWYCOLMITAP<LLIVONTNRPSOVP O RFRARNSGI - SAS, riSLCMEDENIVVCORIMSNISAMMSPOlLTILSOPKAN.SVIL FPPSSEELSANHATIVGLISOF,O.TJAWOOSSMIGOVETTIMI(CSMIMASSYL SLTPECIWKSX.VSCOWTHEGSTVEKTVAPAEGS (SE0 DN.) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT omit IIl °nolo ow (10) International Publication Number WO 2018/164637 Al (51) International Patent Classification: C07K 16/32 (2006.01) G01N 33/53 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/SG2018/050093 (22) International Filing Date: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201701883R 08 March 2017 (08.03.2017) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG). (72) Inventors: WANG, Cheng-I; c/o Singapore Immunology Network, 8A Biomedical Grove, Singapore 138648 (SG). LOW, Lionel; c/o Singapore Immunology Network, 8A Biomedical Grove, Singapore 138648 (SG). GOH, Ange- line; c/o Singapore Immunology Network, 8A Biomedical Grove, Singapore 138648 (SG). WANG, Bei; c/o Singapore Immunology Network, 8A Biomedical Grove, Singapore 138648 (SG). LEE, Wen-Hsin; c/o Singapore Immunology Network, 8A Biomedical Grove, Singapore 138648 (SG). HUANG, Ching-Wen; c/o Singapore Immunology Net- work, 8A Biomedical Grove, Singapore 138648 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: T CELL RECEPTOR LIKE ANTIBODIES THAT BIND TO P53-MHC CLASS I COMPLEX (57) : Antibodies and fragments thereof which bind to peptide-MHC complexes are described. In particular, an antibody binding to a peptide-MHC complex comprising a peptide of p53 and a MHC Class I molecule comprising a-chain encoded by an HLA-A*24 allele is claimed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods of treating, preventing and diagnosing cancers using the same. c-crm MSSSNIEMOYFTN (SFO LC-C131:12: ONINRPS (SEP NCtI LC-CORM OSYLISKL,..1 (SEP 10 NO:I s) 10, PIC1 trn OSYLTOPPSVEAAPOPRVUSCAARYANICMDHONTOOLPER,10-LN2IIIIIMOVP LIRFSGSKSPI SASNI IGIC1,136.NlINCOSYPSNISAWY.601 NI I ILSOPINAFSV I L FPPSSEELOANIGTLYDUSOPIPGAVN,f4.13SSPVKAPVETTI7SKOSMICIAPSSYL 31.173.1.111.50,,HEGSTVEKTVAP.ECS ISE° DN.) LC-CORI: MISTSNIOLISVE111 (SRI 0 NO:20) LC CURS: GNINIVS(ShO IU X01 61 LC COPS: OSNOSKISAWY (00310 NO:IS) SEGMS • OGSPGrII ILSTII S G S S P L E E . K(FLAOS/V CJI W ASOSIGTPAMOOK,NPEP IPL LIYM ASV B F E IPG.IS)ERO SGTOO L INNMV ED KVONAL 00 BV 0 00 NRV TISISS F T-131. L100,SW.IHPGLSS,IO1.1-NliLC,SONKNI)OS II D YLDKVVID e SLO IP F LC-CORI: RASOSIOTO(A 0E0 ID NOM) LC-COM: OASNRAT (SEP ID NO2.) LC-COM: PCRSNWP, (SEC D NOM) ON,TOPSSVSGAPPORVTISC,RMNIANGTOVUWYCOLPETA.KILIT210013MGY PORM01.03010ASUrOLOAE0640 00011(LP/LOOPKAAPS VII.F.PSSEELCANKKILYCLIOMPOPVTVAVIKADBSMOVEHWOENNIGIAS EIVIALTPEOWIMINSYSCQVTHEGSNEN - VAPTECS (SEP D NO., W O 20 18/ 16 4637 Al LC-CDRI: MeSSNIPAGYLIVH (8E010 N021) LC-COM: PHINFIPS MEP 10 NO:251 LC CO: R OSYDENISITIVIV (SE0 10 NO:03) ELSA n OSVLIOPPSVSGAPOOMTIS HWYCOLPSTA.KILIIMINIMOV YOMSOEINSO I SWAN I PLOMDMITIVOOSIDSSISAW , O.0301KUVLOOPIUMPSV .Y.SebbLOININI LYCLISPFTYPt, ,,,KALXISYVING. I I liPSKOGNNIMASS BLIPEOWKSHICSYSCPVTHEGSTVEKTVAPAEM (SEP 1D NO:81 LGCORI: TOMSNIGAMOVN (SEP IP NOV LC-CORI: GINNRPS (6E0 10 NO:25) LC-COM: MYCOSIS/MY (8E310 W.) CBAJOIMSVSOSLOGSMS OCI.K.V101.11YDVSRPcEN RORMORKSONIMI MNI PAMFAO'ffriTIT.Mill VFGPII. IQ FFMISEELOANKATIVC-180FIPOINTV,KADOSPVKAENETTPSKOMICMSTIL SITPEOWKSI.FISYSAJTHEGSNEKNAPAEGS (SEP ID NO 7) LC-CORI: MTSSOVOITINTVS (SEP ID W:213) LC-CORI: OVSSRM :5E010 NOSS) LC-COM: SWITYM0, (SEP IP NO:31) [Continued on next page] WO 2018/164637 Al MIDEDIMOMOIDEIREEMOMOHINIEHINIENVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
SG11201908247R 2017-03-08 2018-03-01 T cell receptor like antibodies that bind to p53-mhc class i complex SG11201908247RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201701883R 2017-03-08
PCT/SG2018/050093 WO2018164637A1 (en) 2017-03-08 2018-03-01 T cell receptor like antibodies that bind to p53-mhc class i complex

Publications (1)

Publication Number Publication Date
SG11201908247RA true SG11201908247RA (en) 2019-10-30

Family

ID=63449067

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908247R SG11201908247RA (en) 2017-03-08 2018-03-01 T cell receptor like antibodies that bind to p53-mhc class i complex
SG10202010600SA SG10202010600SA (en) 2017-03-08 2018-03-01 T cell receptor like antibodies that bind to p53-mhc class i complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202010600SA SG10202010600SA (en) 2017-03-08 2018-03-01 T cell receptor like antibodies that bind to p53-mhc class i complex

Country Status (7)

Country Link
US (1) US20200071406A1 (en)
EP (2) EP3592776A4 (en)
JP (2) JP2020509745A (en)
CN (2) CN110603267A (en)
SG (2) SG11201908247RA (en)
TW (2) TW202116798A (en)
WO (1) WO2018164637A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126626A (en) * 2019-01-29 2022-03-01 磨石生物公司 Multispecific binding proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742650B2 (en) * 1997-10-02 2002-01-10 Altor Bioscience Corporation Soluble single-chain T-cell receptor proteins
US8772451B2 (en) * 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
WO2005083074A1 (en) * 2004-03-01 2005-09-09 Kanazawa University Technology Licensing Organization Ltd. Tumor antigen peptides
US20090226474A1 (en) * 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2567814C (en) * 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
JP6699013B2 (en) * 2014-12-25 2020-05-27 国立大学法人三重大学 WT1-derived peptide recognition antibody
CN108137685B (en) * 2015-03-23 2022-11-11 约翰·霍普金斯大学 HLA-restricted epitopes encoded by somatic mutation genes
WO2016210365A2 (en) * 2015-06-24 2016-12-29 Eureka Therapeutics, Inc. Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
WO2017020974A1 (en) * 2015-08-03 2017-02-09 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
GB201515351D0 (en) * 2015-08-28 2015-10-14 Cancer Res Technology Antibody
JP7374416B2 (en) * 2019-05-23 2023-11-07 株式会社ソミックマネージメントホールディングス rotary damper

Also Published As

Publication number Publication date
WO2018164637A1 (en) 2018-09-13
EP3778646A1 (en) 2021-02-17
US20200071406A1 (en) 2020-03-05
EP3592776A4 (en) 2021-01-06
JP2020509745A (en) 2020-04-02
JP2021072773A (en) 2021-05-13
TW201833133A (en) 2018-09-16
EP3592776A1 (en) 2020-01-15
CN112062860A (en) 2020-12-11
CN110603267A (en) 2019-12-20
SG10202010600SA (en) 2020-12-30
TW202116798A (en) 2021-05-01

Similar Documents

Publication Publication Date Title
SG11201808797XA (en) T cell receptors
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201804038VA (en) Conditionally active heterodimeric polypeptides and methods of use thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201900975XA (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201909602TA (en) Compositions and methods involving probiotic molecules
SG11201909691WA (en) Cementitious composite mat
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201809903WA (en) Method for purification and activation of botulinum neurotoxin
SG11201906961UA (en) Polypeptide variants and uses thereof